Literature DB >> 6747013

Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins.

N J Davidson, J M Sowden, J Fletcher.   

Abstract

Neutrophils from diabetic patients controlled with insulin showed impaired phagocytosis of a yeast, Candida guilliermondii. The defect was detected by measuring the initial rate of phagocytosis at optimal concentrations of phagocytes and organisms in autologous plasma. By mixing normal neutrophils in diabetic plasma and vice versa both cellular and plasma abnormalities were shown. The defect was reproduced by incubating normal plasma at a D-glucose concentration of 15 mmol/l for 3 h or for shorter periods at higher concentrations of glucose. The data suggest that defective phagocytosis is partly due to a reaction between glucose and the plasma proteins concerned with opsonisation. Defective phagocytosis may be important not only in coping with infections but also in other diabetic complications as plasma proteins are concerned with the removal of damaged or effete cells as well as foreign antigens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6747013      PMCID: PMC498809          DOI: 10.1136/jcp.37.7.783

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Diabetes and infection.

Authors:  J F Munro
Journal:  J Antimicrob Chemother       Date:  1976-12       Impact factor: 5.790

2.  Neutrophil dysfunction in diabetes mellitus.

Authors:  J S Tan; J L Anderson; C Watanakunakorn; J P Phair
Journal:  J Lab Clin Med       Date:  1975-01

3.  THE PHAGOCYTIC ACTIVITY OF POLYMORPHONUCLEAR LEUKOCYTES OBTAINED FROM PATIENTS WITH DIABETES MELLITUS.

Authors:  J D BYBEE; D E ROGERS
Journal:  J Lab Clin Med       Date:  1964-07

4.  Mechanism of removal of senescent cells by human macrophages in situ.

Authors:  M M Kay
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  Reversible abnormalities in phagocytic function in poorly controlled diabetic patients.

Authors:  J D Bagdade; K L Nielson; R J Bulger
Journal:  Am J Med Sci       Date:  1972-06       Impact factor: 2.378

6.  Phagocytic and bactericidal capacity of polymorphonuclear leucocytes recovered from venous blood of human beings.

Authors:  B Crosby; F Allison
Journal:  Proc Soc Exp Biol Med       Date:  1966-12

7.  Impaired leukocyte function in patients with poorly controlled diabetes.

Authors:  J D Bagdade; R K Root; R J Bulger
Journal:  Diabetes       Date:  1974-01       Impact factor: 9.461

8.  Leukocyte functions in juvenile diabetes mellitus: humoral and cellular aspects.

Authors:  M E Miller; L Baker
Journal:  J Pediatr       Date:  1972-11       Impact factor: 4.406

9.  Leukocyte chemotaxis in diabetic patients and their nondiabetic first-degree relatives.

Authors:  D M Molenaar; P J Palumbo; W R Wilson; R E Ritts
Journal:  Diabetes       Date:  1976       Impact factor: 9.461

10.  Defective neutrophil function in chronic granulocytic leukaemia.

Authors:  H El-Maalem; J Fletcher
Journal:  Br J Haematol       Date:  1976-09       Impact factor: 6.998

View more
  10 in total

Review 1.  Use of sugar on the healing of diabetic ulcers: a review.

Authors:  Atanu Biswas; Manish Bharara; Craig Hurst; Rainer Gruessner; David Armstrong; Horacio Rilo
Journal:  J Diabetes Sci Technol       Date:  2010-09-01

2.  Changes in phagocytic function with glycaemic control in diabetic patients.

Authors:  S M MacRury; C G Gemmell; K R Paterson; A C MacCuish
Journal:  J Clin Pathol       Date:  1989-11       Impact factor: 3.411

3.  Polymorphonuclear leucocyte dysfunction during short term metabolic changes from normo- to hyperglycemia in type 1 (insulin dependent) diabetic patients.

Authors:  H Kjersem; J Hilsted; S Madsbad; J H Wandall; K S Johansen; N Borregaard
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

4.  Beneficial effects of troglitazone on neutrophil dysfunction in multiple low-dose streptozotocin-induced diabetic mice.

Authors:  Y Kannan; M Tokunaga; M Moriyama; H Kinoshita; Y Nakamura
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

5.  Glycosylated haemoglobin and glucose intolerance in cystic fibrosis.

Authors:  P R Stutchfield; S O'Halloran; J D Teale; D Isherwood; C S Smith; D Heaf
Journal:  Arch Dis Child       Date:  1987-08       Impact factor: 3.791

Review 6.  The impact of diabetes on the pathogenesis of sepsis.

Authors:  G C K W Koh; S J Peacock; T van der Poll; W J Wiersinga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-30       Impact factor: 3.267

7.  Prospective exploration of the effect of adiposity and associated microbial factors on healing and progression of diabetic foot ulcers in Tanzania: study protocol of a longitudinal cohort study.

Authors:  Fredirick Mashili; Agricola Joachim; Said Aboud; Mabulla Mchembe; Faraja Chiwanga; Juliet Addo; Lindsay Kendall; Agbor Ako; Zulfiqar Abbas
Journal:  BMJ Open       Date:  2019-12-16       Impact factor: 2.692

8.  Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential.

Authors:  Silvia Rodriguez-Fernandez; Marta Murillo; Adrian Villalba; David Perna-Barrull; Mary Cano-Sarabia; Laia Gomez-Muñoz; Eva Aguilera; Daniel Maspoch; Federico Vazquez; Joan Bel; Marta Vives-Pi
Journal:  Front Immunol       Date:  2019-11-28       Impact factor: 7.561

Review 9.  A Bittersweet Response to Infection in Diabetes; Targeting Neutrophils to Modify Inflammation and Improve Host Immunity.

Authors:  Rebecca Dowey; Ahmed Iqbal; Simon R Heller; Ian Sabroe; Lynne R Prince
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

10.  Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control.

Authors:  Diana I Gomez; Marcel Twahirwa; Larry S Schlesinger; Blanca I Restrepo
Journal:  Tuberculosis (Edinb)       Date:  2012-11-03       Impact factor: 2.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.